Browse Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Long-term follow-up (f/u) of the phase (Ph) 1/2 CC-99282-NHL-001 study.

e19046 Background: While outcomes in pts with R/R FL have improved with current SOC treatments (Tx), there remains a need for safe, efficacious, and convenient Tx options. GOLCA is a potential, first-in-class, oral CELMoD designed for Tx of lymphoma, with preferential distribution to lymphoid organs and enhanced activity in lymphoma cell lines. GOLCA induces rapid and deep degradation of Ikaros and Aiolos, leading to direct cell killing and immunomodulatory activity. GOLCA + R was well tolerated and effective in heavily pretreated pts in the two-part Ph 1/2 study, CC-99282-NHL-001. Here, we provide longer f/u in pts with R/R FL from Part B of the study. Methods: Pts with R/R FL with ≥2 prior lines of Tx (≥1 if prior anti-CD20 Tx) received GOLCA orally, once daily at 0.2 mg (n=22) or 0.4 mg (n=38) ± R for up to 2 y or until progressive disease (PD)/unacceptable toxicity. Primary endpoints included safety and RP2D determination; secondary endpoints are preliminary efficacy and PK. Results: As of September 15, 2025, 60 pts were enrolled. In 0.2 and 0.4 mg groups, median prior Tx lines were 3 and 3, 32% and 32% had prior lenalidomide (LEN), 27% and 29% had prior T-cell–redirecting Tx (CAR T and/or bispecific antibody) and 32% and 32% were refractory to last regimen. Tx is ongoing in 6 (27%) and 17 (45%) pts at 0.2 and 0.4 mg, respectively; discontinuations (d/c) were mostly due to PD. Neutropenia, an on-target side effect of GOLCA, was the most common grade 3/4 Tx-emergent adverse event (TEAE) occurring in 59% and 68% of pts at 0.2 and 0.4 mg, followed by anemia (9% and 16%) and febrile neutropenia (9% and 8%). Median time to resolution of neutropenia was 8 days. Dose reductions occurred in 14% and 37% of pts at 0.2 and 0.4 mg, most commonly due to neutropenia (5% and 21%) and febrile neutropenia (5% and 5%). No d/c or deaths were from GOLCA-related TEAEs. Non-hematologic TEAEs were infrequent and mostly low grade. In efficacy-evaluable pts (GOLCA 0.2 and 0.4 mg + R, n=22 and n=36), median f/u was 14.03 months (mo), overall response rate (ORR) was 77% (complete response rate [CRR], 41%) at 0.2 mg, and 97% (CRR, 78%) at 0.4 mg. In the 0.4 mg group, responses were consistent in high-risk subsets including pts with prior LEN (ORR, 100%; CRR, 75%) and/or T-cell–redirecting Tx (ORR, 91%; CRR, 64%). GOLCA 0.4 mg + R demonstrated durable responses (median DOR, 9.17 mo; 91% of pts who achieved a CR remained in CR at cutoff). Conclusions: With longer f/u, GOLCA + R demonstrated promising efficacy with durable responses and no new safety signals. The 0.4 mg group had higher ORR and CRR than 0.2 mg, including in pts with prior LEN-based and/or T-cell–redirecting Tx, with a manageable safety profile at both doses. The results support the development of GOLCA + R as a fixed-duration, chemotherapy-free outpatient Tx in the Ph 3 GOLSEEK-4 study in 2L+ FL (NCT06911502). Clinical trial information: NCT03930953 .

Graphene-based diplexer for THz nanophotonic wireless links

Challenges and Opportunities of Oligomeric Acceptors Toward Efficient and Stable Organic Photovoltaics

ABSTRACT High power conversion efficiency (PCE) and long‐term operational stability are essential prerequisites for the commercialization of organic solar cells (OSCs). Small‐molecule acceptors (SMAs) have driven remarkable advances in OSC performance, enabling continuous breakthroughs in device efficiency. However, OSCs based on SMAs generally suffer from poor long‐term stability, which severely limits their practical application. This instability primarily originates from the low glass transition temperatures ( T g ) of SMAs, resulting in rapid molecular diffusion and aggregation, as well as morphological degradation of the active layer, leading to a subsequent decrease in device performance. Oligomeric small‐molecule acceptors (OSMAs) have recently emerged as a promising molecular design strategy to overcome these challenges. OSCs incorporating OSMAs have achieved impressive PCEs approaching 20%, while simultaneously exhibiting outstanding photothermal and mechanical stability. In this perspective, we systematically review recent progress in OSMA‐based OSCs and discuss the key factors governing their efficiency and stability, including molecular structure, aggregation behavior, and morphology evolution. Finally, we outline the current challenges and future opportunities for OSMA materials in advancing high‐performance and durable OSC technologies.

Real-world evidence of tazemetostat in epithelioid sarcoma patients.

e23539 Background: Epithelioid sarcoma (ES) is an ultra-rare and aggressive mesenchymal soft tissue sarcoma (STS) with limited therapeutic options. Therapies targeting EZH2 have shown promise, with tazemetostat being the first FDA-approved treatment for this histology. Tazemetostat was approved in Hainan (Boao Lecheng International Medical Tourism Pilot Zone) in May 2022, but has not received approval for the rest of mainland China. Several ES patients (pts) have been treatment with tazemetostat in Hainan. Here we present a retrospective analysis of ES pts treated with tazemetostat-based regimens at Ruijin Hainan Hospital, and this analysis was the first report on tazemetostat in Chinese ES pts. Methods: We retrospectively reviewed all pts with histologically confirmed ES treated with tazemetostat-based regimens at Ruijin Hainan Hospital between 2022 and 2025. Patient demographics, disease characteristics, treatment regimens, and clinical outcomes were collected. Endpoints included real-world progression-free survival (rwPFS), overall survival (OS), and safety. Results: Nineteen advanced ES pts with loss of SMARCB1/INI1 received tazemetostat-based regimens. The median age was 35 years (Range: 16-69), with 68.42% female pts. The two clinical subsets comprise 9 patients of the distal type and 10 patients of the proximal type. Patients received a median of 2 lines of previous therapies (range 1-5), with 8 pts (42.11%) receiving tazemetostat-based regimens as a first-line treatment. Most pts (n=13) had previously received chemotherapy (most anthracycline, n=12), anti-angiogenic targeted therapy (n=10), and immune checkpoint inhibitors (n=3). 14 pts received tazemetostat monotherapy, and 5 pts received tazemetostat combined with immunotherapy. As of August 30, 2025, with a median follow-up of 15.51mo (range: 1.08-24.44), median rwPFS was 10.55mo (95% CI: 7.62-NE) with 12-mo and 18-mo PFS of 41% (95% CI: 15-100%) and 20% (95% CI: 4-100%). Median OS was 17.18mo (95% CI: 4.24-NE) with 12-mo and 24-mo OS of 52% (95% CI: 32-84%) and 26% (95%CI: 9%-77%).In different subsets, the PFS was 17.22mo for distal-type and 7.62mo for proximal-type. Median PFS was 13.33mo in treatment-naïve pts and 10.55mo in previously treated pts. Favorable PFS was observed in combination regimens compared with tazemetostat monotherapy (7.62 vs 13.89mo). Compared with pts who received anti-angiogenic targeted therapy in prior therapy, pts without showed longer PFS (10.55mo vs 13.36mo, p=0.11). Treatment-emergent adverse events (TEAEs) were mostly mild (grade 1-2), the most common were hemorrhage (21%), vomiting (21%), decreased white blood cell count (16%), AST increased (16%), decreased lymphocyte count (16%), and anemia (16%). Grade 3-4 TEAEs were recorded in 1 pt with decreased platelet count. Conclusions: The median rwPFS of 10.55 months demonstrated the efficacy of tazemetostat in advanced ES patients. Updated data will be presented in the future.

PIN1, cholesterol biosynthesis, and clinical outcomes in urothelial carcinoma (UC): A propensity-weighted real-world clinicogenomic analysis.

e16575 Background: PIN1 is a phosphorylation-dependent prolyl isomerase that regulates oncogenic pathways, including cancer stemness, epithelial–mesenchymal transition, immune modulation, and cholesterol biosynthesis. While mechanistic studies implicate PIN1 in aggressiveness across cancer types, its clinical relevance in UC remains unclear. Methods: The Tempus Lens platform was used to identify a real-world cohort of patients (pts) with UC that underwent DNA (Tempus xT) and RNA (Tempus xR) sequencing (N = 4,886). Short variants and copy number changes are reported in our analysis. RNA data were quantified as transcripts per million (TPM) and reported as log2(TPM+1). Pts were classified as PIN1 high (PIN1-h, N = 1,157) or low (PIN1-l, N = 1,211) based on top and bottom mRNA expression quartiles. Single-sample gene set enrichment analysis (ssGSEA) was used to characterize enrichment in MSigDB Hallmark and cholesterol related metabolic pathways. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were measured from initiation of first line (1L) therapy and sample collection date respectively. Propensity score weighting was used for balancing hyperlipidemia history and biopsy site. Hazard ratios (HR) were calculated using multivariable Cox regression. Median rwOS estimated using Kaplan–Meier curves and compared using log-rank tests. Results: The cohort was composed of pts with bladder (83%) and upper tract (17.2%) UC. Of pts with documented staging, 62.9% were metastatic and 16% had a history of hyperlipidemia. PIN1-h tumors were enriched in pathways suggesting increased lipid biosynthesis such as cholesterol regulation ( q < 0.001), glycerolipid metabolism (q < 0.001) and SREBF signaling (q < 0.004) as well as in oncogenic pathways (WNT/Beta Catenin, Notch, p53, KRAS). Immune-signatures (IL6, JAK STAT3 , IFNa, IFNγ) showed decreased enrichment in PIN1-h. Somatic alterations differed, with PIN1-h tumors having higher prevalence of tumor suppressor gene alterations TP53 (68% vs 54%) and RB1 (23% vs 16%) and lower rates of alterations in FGFR3 (11% vs 18%) and ARID1A (18% vs 27%), consistent with aggressive disease biology. rwPFS was shorter in pts with PIN1-h vs PIN1-l tumors when treated with 1L chemotherapy (HR 3.01, 95% CI 1.43-6.33; p = 0.004) but not 1L immunotherapy. Paradoxically, pts with PIN1-h tumors showed a modest but statistically significant improvement in rwOS (HR 0.85, 95% CI 0.74–0.98; p = 0.030). Median rwOS was longer for PIN1-h vs PIN1-l (12.1 vs 15.5 months, p = 0.026). Conclusions: PIN1 expression identifies a distinct subset of UC characterized by cholesterol pathway enrichment and aggressive genomic features. While PIN1-h tumors show shorter rwPFS on 1L chemotherapy, they exhibit longer rwOS overall. These opposing outcomes highlight PIN1 as a complex, potentially treatment-specific prognostic biomarker.

A health systems analysis of global head and neck cancer outcomes.

e18092 Background: Head and neck cancers (HNC) remain a major global cause of cancer morbidity and mortality, with disproportionately poor outcomes in low- and middle-income countries. Marked cross-national disparities suggest an important role for health system strengthening. We evaluated associations between national health system characteristics and global HNC outcomes. Methods: We conducted a cross-sectional ecological analysis of 185 countries using sex-stratified, age-standardized incidence and mortality estimates from the International Agency for Research on Cancer (IARC) GLOBOCAN 2022 database. The primary outcome was the composite mortality-to-incidence ratio (MIR) for aggregated HNCs, including cancers of the lip and oral cavity, oropharynx, larynx, nasopharynx, hypopharynx, and salivary gland. We evaluated 11 national health system indicators spanning health financing, workforce density, service availability, socioeconomic development, and gender equity. Univariable linear regressions identified candidate variables using Bonferroni correction (P<0.0045), followed by multivariable modeling with assessment for multicollinearity using variance inflation factor analysis (VIF>10 prompting removal). Results: All 11 health system indicators were significantly associated with HNC MIR in univariable analyses (P<.001 for all). In multivariable analysis restricted to countries with complete covariate data (n=123), higher Universal Health Coverage (UHC) service coverage index and higher gross domestic product (GDP) per capita were independently associated with lower (improved) HNC MIR. The model demonstrated strong predictive power (model R²=0.70; VIF for all <10). On analysis stratified by sex, UHC index and GDP per capita were similarly independently associated with improved MIR for HNCs. Conclusions: Our global cross-national analysis demonstrates that universal health coverage and national economic capacity are independently associated with improved head and neck cancer mortality-to-incidence ratios, underscoring the central role of health system strength in shaping outcomes. These findings highlight how investments in healthcare access, financial protection, and resource availability may help narrow global disparities in HNC.

Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01.

TPS8665 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in NSCLC, yet primary and secondary resistance remain common, limiting durable benefit. Growth differentiation factor 15 (GDF-15) has been implicated in ICI resistance. Clinical data for the anti–GDF-15 antibody visugromab in combination with nivolumab have been presented, demonstrating reinvigoration with deep and durable responses in relapsed/refractory solid tumors and increased efficacy in an ICI-naïve neoadjuvant setting, strongly supporting further evaluation in ICI-naïve NSCLC. This trial estimates the added clinical activity and safety of visugromab with standard chemo-immunotherapy and addresses primary immune resistance in first-line metastatic non-squamous NSCLC. Methods: GDFATHER-NSCLC-01 is a phase 2b, multicenter trial with an initial safety-run-in (SRI) followed by a randomized, double-blind, placebo-controlled part, conducted at >40 sites in seven countries across the US and Europe. The SRI employs a 3+3 dose escalation (two predefined visugromab dose levels; DLT window of 21 days) to determine the recommended dose for expansion; an independent data monitoring committee oversees escalation and the selection of the expansion dose. In the randomized part, participants with untreated metastatic non-squamous NSCLC (no actionable driver mutations), ECOG 0–1, are assigned 2:1 to receive visugromab or placebo in combination with pembrolizumab, pemetrexed, and carboplatin (21-day cycles). Brain metastases are allowed if untreated, asymptomatic and clinically stable, or if previously treated and stable per protocol. Patients are stratified according to PD-L1 tumor proportion score (<1% vs 1–49% vs ≥50%). The primary endpoint of the trial is objective response rate (RECIST v1.1). Key secondary endpoints include duration of response, progression-free survival, overall survival, safety, pharmacokinetics, and patient-reported outcomes; exploratory biomarker analyses are planned. The randomized part is not powered for statistical significance; the planned sample size is 90 participants, enabling descriptive estimation of effect sizes to inform future pivotal development. Enrollment status: The SRI has been completed. The randomized part is open to accrual; first patient pending. Clinical trial information: NCT07098988 .

OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2- advanced breast cancer.

TPS1152 Background: Estrogen receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (ER+, HER2- ABC) accounts for nearly 70% of all ABC. The standard first-line treatment for ER+, HER2- ABC is the combination of an aromatase inhibitor (AI) with cyclin–dependent kinase 4/6 inhibitor (CDK4/6i). When combined with AI, the CDK4/6i ribociclib has demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in this setting. Despite these advances, resistance to AI + CDK4/6i develops in a substantial proportion of patients (pts), most commonly driven by acquired mutations in the ligand-binding domain of ERα, resulting in constitutive ligand-independent ER activation. Early and sustained suppression of both wild-type and mutated ERs in the first line treatment of ER+, HER2- ABC may enhance endocrine sensitivity, delay resistance to endocrine therapy and improve clinical outcomes. Palazestrant (OP-1250) is an investigational oral, complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). In early phase studies, palazestrant has shown favorable safety and encouraging antitumor activity as monotherapy (Hamilton et al, 2025) and in combination with ribociclib (Lin et al, 2025), regardless of ESR1 mutation status, including in those previously treated with CDK4/6i. Palazestrant showed no clinically meaningful drug-drug interactions with ribociclib, and the combination safety profile was consistent with the known profiles of each drug. Methods: OPERA-02 (NCT07085767) is a phase 3, international, multicenter, randomized, double-blind, study designed to evaluate the efficacy and safety of palazestrant plus ribociclib versus letrozole plus ribociclib in the first line treatment of pts with ER+, HER2- ABC. Approximately 1,000 pts will be randomized 1:1 to either palazestrant plus ribociclib or letrozole plus ribociclib, with matching placebos. The primary endpoint is investigator-assessed PFS; secondary endpoints are OS, PFS by a blinded-independent review committee, overall response rate, duration of response, clinical benefit rate, safety, pharmacokinetics, pt-reported outcomes and PFS2. Eligible pts are adult women, regardless of menopausal status, and men, with de novo or recurrent disease (≥ 12 months after completion of adjuvant endocrine therapy) who have not received prior systemic therapy for ER+, HER2- ABC. Pts must have measurable disease per RECIST 1.1 or evaluable bone disease, ECOG performance score of 0-1, and adequate organ function. Pts with a contraindication to ribociclib are excluded. Pre- or perimenopausal women and men must receive gonadotropin-releasing hormone (GnRH) agonists for gonadal function suppression. The study has been recruiting globally since November 2025. Clinical trial information: NCT07085767 .

A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted ¹⁷⁷ lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.

TPS11587 Background: Treatment for relapsed and refractory (R/R) osteosarcoma (OST) has not changed for decades. R/R OST has a poor prognosis with a 12% 4-month event-free survival (EFS). Leucine-Rich Repeat Containing 15 (LRRC15) is a type I transmembrane protein on OST cells and cancer associated fibroblasts. Approximately 90% of OST express LRRC15; high expression predicts aggressive disease and shorter survival. LNTH-2403 is a high-affinity LRRC15-targeting fully humanized antibody with a 177 lutetium payload. Preclinical data show anti-tumor activity in several OST models, demonstrating LNTH-2403’s potential to treat R/R OST. Methods: This first-in-human, multicenter, open-label phase 1/2 study will evaluate the safety, tolerability, pharmacokinetics (PK), biodistribution (BD), radiation dosimetry (RD), and preliminary anti-neoplastic activity in patients ≥12 years of age with LRRC15-expressing R/R OST. The primary endpoints are to identify the maximum tolerated dose (MTD; phase 1) and 4-month EFS (phase 2). LRRC15 expression by immunohistochemistry will be confirmed by a central lab; pre-screening is allowed. Initiated in Q1 2026, phase 1 will test LNTH-2403 at 30, 50, and 70 mCi/m 2 every 8 weeks in up to ~30 patients. A 3+3 design will be used to define the MTD and estimate the recommended phase 2 dose (RP2D). Phase 2 will evaluate LNTH-2403 at the RP2D in ~25 patients with R/R OST. Retreatment after Cycle 1 is permitted for patients who continue to meet initial eligibility requirements, have cumulative doses to target organs predicted to be below radiation tolerance limits, and whose bone marrow has recovered. Safety testing includes adverse events (AEs), serious AEs (SAEs), laboratory parameters (chemistry, hematology, coagulation, urinalysis), electrocardiograms, vital signs, and physical examinations. BD and RD are based on serial single photon emission computed tomography (SPECT)/computed tomography (CT) and planar imaging. PK data will be generated from serial blood sampling for radioactivity. Overall response rate (ORR) and EFS are defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator reads. As ORR by RECIST is challenging in OST due to tumor calcification, efficacy testing also includes physiologic response by fluorine-18 ( 18 F)-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT whole body scans and magnetic resonance imaging of the primary site, sites of known and presumed metastases, and the chest, abdomen, and pelvis. For this open-label study, all statistical methods will be descriptive in nature with no formal statistical hypotheses. NCT07357519; Research Sponsor: Lantheus. Clinical trial information: NCT07357519 .

Real-world study on the effect of PARPi as maintenance therapy on recurrent site after first-line chemotherapy in patients with high-grade serous epithelial ovarian cancer.

e17593 Background: This study investigated the effect of poly (ADP-ribose) polymerase inhibitors (PARPi) as maintenance therapy after first-line chemotherapy on recurrent site in patients with high-grade serous epithelial ovarian cancer (HGSOC). Methods: This study retrospectively analyzed 173 patients with HGSOC treated at Zhejiang Cancer Hospital and Jiaxing Maternity and Child Health Care Hospital between January 2017 and March 2024. The PARPi group comprised patients who received a PARPi as maintenance therapy after first-line chemotherapy (n=63), and the control group comprised those who did not (n=110). Results: There were no differences in both groups regarding age, body mass index (BMI), residual tumor after initial surgery, efficacy evaluation after first-line chemotherapy (P > 0.05). Among the 63 patients in the PARPi group and the 110 patients in the control group, thirty-eight and 28 whose recurrent site were widespread pelvic and abdominal peritoneum, respectively (hazard ratio [HR]: 2.37, 95% Confidence Interval (CI) 1.63-3.47, P < 0.0001). However, there was no significant statistical difference in lymph nodes recurrence between the two groups (HR: 0.95, 95% CI 0.69-1.26, P=0.72). In the subgroup analysis of the PARPi group, among 36 patients with breast cancer susceptibility gene (BRCA) mutations and 10 homologous recombination deficiency(HRD) negative patients, 21 and 7 patients developed pelvic and abdominal peritoneum recurrence (HR: 0.83, 95% CI 0.54-1.54, P=0.50), while 20 and 5 patients developed lymph node recurrence (HR: 1.11, 95% CI 0.63-2.45, P=0.75) respectively, with no statistically significant differences. Conclusions: Patients with HGSOC using a PARPi as maintenance therapy after first-line chemotherapy were more likely to cause widespread pelvic abdominal peritoneal recurrence while lymph node recurrence were similar to those who did not receive PARPi. BRCA status did not affect the recurrent site when using a PARPi as maintenance therapy after first-line chemotherapy. We should pay attention to these patients because using a PARPi as maintenance therapy after first-line chemotherapy might change the location and characteristics of recurrent lesions, which might affect the complete resection rate of secondary cytoreductive surgery Recurrence site analysis. Widespread pelvic abdominal peritoneal recurrence No widespread pelvic abdominal peritoneal recurrence Total PARPi 38 25 63 no PARPi 28 82 110 Total 66 107 173 Lymph node recurrence No lymph node recurrence Total PARPi 32 31 63 no PARPi 59 51 110 Total 91 82 173 widespread pelvic abdominal peritoneal recurrence no widespread pelvic abdominal peritoneal recurrence Total BRCA1/2 mutation 21 15 36 HRD negative 7 3 10 Total 28 18 46 Lymph node recurrence no Lymph node recurrence Total BRCA1/2 mutation 20 16 36 HRD negative 5 5 10 Total 25 21 46

Impact of transfusion timing on clinical outcomes across hematologic malignancies.

e18613 Background: Transfusion support is essential in the inpatient management of hematologic malignancies; however, disease-specific differences in transfusion timing, blood bank processing delays and their association with clinical outcomes remain poorly studied. We sought to evaluate whether these factors are independently associated with hospital length of stay (LOS) and in-hospital mortality. Methods: We performed a retrospective cohort study of 2,415 red blood cell (RBC) and platelet transfusion events among hospitalized patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM) at a tertiary care center from October 2022 to October 2025. Transfusion timing variables included day versus night administration (7:00 AM–6:59 PM vs 7:00 PM–6:59 AM), weekday versus weekend administration, STAT priority orders and blood bank issue lag (time from order placement to product release). Outcomes were LOS and in-hospital mortality. Diagnosis-specific differences were evaluated using chi-square testing and ANOVA. Multivariable linear regression and logistic regression models were incorporated to test independent associations between transfusion-related variables and outcomes, and adjusted for diagnosis. Results: RBCs accounted for 42.5% (674/1,585), 45.7% (252/552) and 76.6% (213/278) of transfusions in AML, ALL and MM, respectively, with platelets comprising 911, 300 and 65 transfusions (p<0.001). Night transfusions differed modestly (18.3% AML, 14.3% ALL, 21.9% MM; p=0.017), whereas weekend transfusions varied more substantially (24.9% AML, 18.3% ALL, 30.9% MM; p<0.001). STAT utilization also differed by diagnosis (31.5% AML, 21.6% ALL, 23.7% MM; p<0.001). Blood bank issue lag differed significantly (p<0.001), longest in MM (2.97 hours) compared with ALL (2.50 hours) and AML (2.26 hours). Mean LOS was 36.7 days for AML, 21.3 days for ALL and 17.0 days for MM (p<0.001). In-hospital mortality occurred in 52.6% of AML, 22.1% of ALL and 48.2% of MM patients (p<0.001). After adjustment, weekend transfusions were independently associated with longer LOS (β=0.154, p=0.033), while STAT priority orders were associated with shorter LOS (β=−0.087, p=0.028). STAT priority was independently associated with increased odds of in-hospital mortality (OR 1.46, 95% CI 1.20–1.77; p<0.001). Time of day and issue lag were not independently associated with outcomes. Conclusions: Transfusion timing, issue lag and clinical outcomes differed significantly by diagnosis among patients with AML, ALL and MM. STAT priority was the strongest independent predictor of outcomes, reflecting greater illness severity. Weekend transfusions were associated with longer LOS, potentially related to system-level factors affecting care coordination. Chronic leukemias were excluded due to limited sample size.

Association of triple-negative breast cancer with decreased T score of femoral neck at the time of osseous metastasis.

e13132 Background: While agents are administered when indicated, skeletal vulnerability may vary ; however, molecular subtype-specific differences in bone mineral density(BMD) in patients at the time of bony metastasis yet to be clearly delineated. Methods: This retrospective cohort study included patients with breast cancer with bone metastasis treated between January 2000 and December 2022. The median follow-up period was 36 months or longer. T-scores of femoral neck and lumbar spine at the time of bone metastasis were the primary skeletal outcome, and serum 25-hydroxyvitamin D and pyridinoline were analyzed as representative bone metabolism markers. Multivariable linear regression was used to evaluate factors associated with BMD. Results: A total of 184 patients with bone metastasis were analyzed (luminal A, n = 104; luminal B, n = 41; HER2-enriched, n = 16; TNBC, n = 23). The interval from initial diagnosis to bone metastasis differed significantly by subtype, with luminal subtypes showing the longest latency and TNBC the shortest. Femoral neck T-scores varied significantly across subtypes, with TNBC demonstrating the lowest mean values, whereas lumbar T-scores did not differ significantly. Biochemical markers of bone metabolism was subtype-specific. TNBC patients had lower serum 25-hydroxyvitamin D levels and higher pyridinoline levels, consistent with increased bone turnover. The prevalence of osteoporosis, vitamin D deficiency, and a composite high-risk skeletal phenotype was highest in TNBC compared with others. In multivariable analyses adjusting for age, body mass index, and treatment-related factors, TNBC remained independently associated with lower femoral neck T-scores. Conclusions: Bone mineral density differ substantially by subtype in breast cancer at the time of bone metastasis. TNBC is associated with pronounced skeletal vulnerability, characterized by reduced bone mineral density and adverse bone metabolic profiles, independent of endocrine therapy exposure. Multivariable linear regression analysis of factors associated with femoral bone mineral density. Variable Model 1 β (95% CI) Model 2 β (95% CI) Model 3 β (95% CI) Luminal B −0.18 (−0.45 to 0.08) −0.15 (−0.42 to 0.11) −0.12 (−0.38 to 0.14) HER2-enriched 0.22 (−0.12 to 0.56) 0.19 (−0.15 to 0.53) 0.17 (−0.16 to 0.50) TNBC −0.63 (−0.94 to −0.32) −0.58 (−0.89 to −0.27) −0.52 (−0.83 to −0.21) Age (per year) −0.03 (−0.04 to −0.02) −0.03 (−0.04 to −0.02) −0.03 (−0.04 to −0.02) Body mass index (kg/m²) 0.07 (0.03 to 0.11) 0.06 (0.02 to 0.10) 0.05 (0.01 to 0.09) Postmenopausal status −0.31 (−0.58 to −0.05) −0.28 (−0.54 to −0.02) −0.24 (−0.50 to 0.01) Aromatase inhibitor use −0.26 (−0.49 to −0.03) −0.22 (−0.45 to 0.01) −0.18 (−0.40 to 0.04) Model 1 included molecular subtype only. Model 2 was adjusted for age and body mass index. Model 3 was additionally adjusted for menopausal status and aromatase inhibitor use.

Defining the role of locoregional radiotherapy for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era: A systematic review and meta-analysis.

6039 Background: In the pre-immunotherapy era, a phase 3 randomized controlled trial (NCT02111460) confirmed locoregional radiotherapy (LRRT) combined with palliative chemotherapy improved overall survival (OS) and progression-free survival (PFS) in de novo metastatic nasopharyngeal carcinoma (dmNPC). Consequently, this strategy has been adopted by major clinical practice guidelines, including NCCN, CSCO, and ESMO. However, with immunotherapy now integrated into first-line treatment, the contemporary role of LRRT and the definition of patients most likely to benefit from it are uncertain and necessitate further exploration. Methods: This meta-analysis was conducted in accordance with PRISMA guidelines. A comprehensive search was conducted in electronic databases including PubMed, Cochrane Library, and Web of Science from their inception to December 31, 2025, to identify eligible studies comparing immunochemotherapy with or without LRRT in dmNPC. The primary outcomes were PFS and OS. Meta-analysis was performed using OnlineMeta V1.1. Results: A total of six clinical trials were rated as high-quality and included in this meta-analysis. Our meta-analysis results showed that the palliative immunochemotherapy (PICT) plus LRRT group achieved significantly longer PFS (HRs: 0.560, 95%CIs: 0.431-0.727) and OS (HRs: 0.502, 95%CIs: 0.289-0.869) than the PICT alone group. Additionally, single-arm meta-analysis results demonstrated that the 1-year, 2-year, and 3-year PFS rates (with 95% CIs) in the PICT plus LRRT group were 80.5% (76.3%-84.2%), 56.3% (53.7%-58.9%), and 37.6% (28.6%-47.5%), compared with 62.7% (56.2%-68.8%), 26.3% (16.8%-38.7%), and 7.6% (2.4%-21.6%) in the PICT group. Regarding OS, the 1-year, 2-year, and 3-year rates (with 95% CIs) were 97.1% (95.3%-98.2%), 84.2% (72.3%-91.6%), and 76.0% (47.4%-91.7%) in the PICT plus LRRT group, whereas those in the PICT group were 76.9% (33.5%-95.7%), 55.8% (13.7%-90.9%), and 39.7% (1.7%-88.4%). Sensitivity analysis confirmed the stability of the results, and no significant publication bias was detected. Subgroup analyses indicated that dmNPC patients achieved greater PFS benefit from LRRT when they had partial or complete response to PICT (HRs: 0.509, 95%CIs: 0.368-0.704), undetectable post-treatment EBV DNA (HRs: 0.541, 95%CIs: 0.378-0.774), or oligometastatic disease (HRs: 0.349, 95%CIs: 0.193-0.634). Conclusions: In the immunotherapy era, LRRT combined with PICT confers significant and durable survival benefits for dmNPC patients, with pronounced efficacy among those achieving PR/CR to PICT, harboring undetectable post-treatment EBV DNA, or presenting with oligometastatic disease.

Real-world outcomes of abiraterone in metastatic prostate cancer: A multicenter study in Peru.

e23405 Background: Prostate cancer accounts for 14% of cancers in men in Peru. Although abiraterone acetate was approved by the FDA in 2011, access through the Peruvian public health system has been available only since 2022, raising questions about its real-world effectiveness in both metastatic castration-sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC). Our objective was to describe the clinicopathological characteristics and outcomes of patients treated with abiraterone across metastatic prostate cancer settings in 4 oncology centers nationwide in Peru. Methods: A retrospective cohort study of patients with metastatic prostate cancer treated with abiraterone at 4 oncology centers in Peru: Instituto Nacional de Enfermedades Neoplásicas (INEN), Instituto Regional de Enfermedades Neoplásicas del Sur (IREN SUR), Hospital Centro Médico Naval (CEMENA), and Hospital Regional Guillermo Díaz de la Vega (HRGDV), between 2022-2025. Descriptive statistics and Kaplan–Meier methods were used to assess clinicopathological characteristics, radiographic progression-free survival (rPFS), and overall survival (OS). Results: 113 patients were included. Abiraterone acetate was used in mCSPC setting in 30% (mean age 71.5 years; mean PSA 166 ng/mL) and in mCRPC setting in 70% (mean age 71.2 years; mean PSA 2,535 ng/mL). Histology was acinar adenocarcinoma in mCSPC:97.1% and mCRPC: 93.7%. Gleason score distribution in mCSPC was: 1:2.9%; 2:2.9%; 3:17.6%; 4: 44.2%; 5: 29.5%; unknown:2.9%, in mCRPC: 1:2.5%; 2:11.4%; 3: 21.5%; 4: 25.3%; 5:32.9%; unknown:6.3%. By LATITUDE risk classification, mCSPC patients were high risk 44.1% and low risk 55.9%. The main metastatic sites in mCSPC were bone 85.3%, nodal 47.1%, and visceral 14.7%; in mCRPC bone 92.4%, nodal 35.4%, and visceral 10.9%. In mCSPC, treatment comprised triplet therapy (abiraterone–docetaxel–ADT): 2.9% and doublet therapy (abiraterone–ADT): 97.1%. In mCRPC, prior treatments were bicalutamide–ADT 72.2%, docetaxel–ADT 16.5%, and ADT alone 11.3%. RECIST response in mCSPC showed partial response (PR): 88.2%, complete response (CR): 5.9%, and progressive disease (PD):5.9%. In first-line mCRPC, abiraterone: 65.8%, docetaxel:29.1% and palliative care: 5.1%. RECIST responses comparing abiraterone versus docetaxel were: abiraterone PR 41.3%, PD 16.0%, stable disease (SD) 12.0%; docetaxel PR 14.7%, PD 13.3%, SD 2.7%. With a median follow-up of 41.3 months, 3 years rPFS was mCSPC: not reached; mCRPC rPFS at 3 years was 43.4% in the pre-docetaxel setting and 4.3% post-docetaxel. 3 years OS was mCSPC: 90.7% and mCRPC 80.1%. Conclusions: In real-world practice in Peru, abiraterone demonstrated efficacy and survival comparable to pivotal trials, with superior outcomes in mCSPC. Despite 44% high-risk disease, triplet therapy was rarely used and most patients received ADT alone or with bicalutamide, limiting its population-level benefit.

Clonal hematopoiesis as a predictor of immune toxicity and efficacy after chimeric antigen receptor T-cell therapy: A systematic review and meta-analysis.

7039 Background: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with age-related inflammation and may influence immune toxicity and efficacy after CAR T-cell therapy, although reported associations are inconsistent. We performed a systematic review and meta-analysis to quantify CHIP associations with CAR-T toxicities and response. Methods: We conducted a systematic review and meta-analysis of comparative studies reporting CAR-T outcomes by sequencing-defined CHIP status. PubMed, Embase, Cochrane Central, and Web of Science were searched through 2025; nine observational studies were included from 3,529 records. The evidence comprised nine retrospective cohorts (n=869) of adults receiving commercial CD19 CAR-T for B-cell malignancies (mainly aggressive lymphoma/LBCL, B-ALL) or BCMA CAR-T for multiple myeloma. CHIP was identified from pre-infusion blood-derived samples using targeted myeloid sequencing, typically at VAF ≥2% (range >0.3%–≥2%; one study ≥1%), with prevalence 16–56%. Primary endpoints were ASTCT grade ≥3 CRS and ICANS; secondary endpoints included CRS ≥2, any-grade ICANS, ORR, and CR. Risk ratios were pooled using random-effects Mantel–Haenszel models with prespecified subgroup and sensitivity analyses by CAR target/disease; risk of bias was assessed with ROBINS-I. Results: Four cohorts (n=360; 2 CD19, 1 BCMA, 1 mixed) contributed to primary toxicity analyses. CHIP was not associated with severe CRS (ASTCT ≥3; 8/172 vs 14/188; RR 0.72, 95% CI 0.24–2.13; I²=31%) or severe ICANS (RR 1.16, 95% CI 0.48–2.81; I²=39%), with wide confidence intervals reflecting low event counts. A CD19-restricted sensitivity analysis demonstrated higher risk of severe ICANS among CHIP-positive patients (RR 1.66, 95% CI 1.03–2.65; I²=0%). For moderate-to-severe CRS (ASTCT ≥2), five cohorts (n=456) showed no association (RR 1.04, 95% CI 0.73–1.48; I²=59%); exclusion of a mixed cohort reduced heterogeneity and remained null (RR 1.02, 95% CI 0.79–1.32; I²=18%). Any-grade ICANS was not increased (six cohorts, n=440; RR 1.10, 95% CI 0.85–1.41; I²=1%). Efficacy was preserved: ORR was modestly higher in CHIP-positive patients in full-text cohorts (n=347; RR 1.14, 95% CI 1.02–1.27; I²=0%), with similar estimates when including abstract-only data (RR 1.10, 95% CI 1.01–1.21). CR showed a small overall increase (n=385; RR 1.24, 95% CI 1.01–1.52; I²=15%) that was not robust on sensitivity analysis (RR 1.23, 95% CI 0.90–1.67). Conclusions: CHIP was not consistently associated with CRS severity or overall ICANS incidence after CAR-T therapy, although severe ICANS may be higher in CD19 CAR-T lymphoma. Efficacy was preserved in CHIP-positive patients, with no evidence of impaired ORR or CR, and observed response differences should be interpreted cautiously given observational design and heterogeneous definitions.

LuSato-1: Phase I study of ¹⁷⁷ Lu-SSO110 with ⁶⁸ Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).

8011 Background: Outcomes for pts with ES-SCLC remains suboptimal despite the addition of ICIs to platinum-based chemotherapy. Somatostatin receptor 2 (SSTR2) is expressed in the majority of SCLC lesions. SSTR2 targeted radiopharmaceutical therapy (RPT) has proven safe and effective when used in other neuroendocrine tumors. The multicentre, open-label, phase I LuSato-1 (ACTRN12623000185662) study investigated the use of 177 Lu-satoreotide Tetraxetan ( 177 Lu-SSO110) with 68 Ga-Satoreotide Trizoxetan ( 68 Ga-SSO120) companion imaging in pts with ES-SCLC, who are on 1L maintenance ICIs. Methods: Adult pts with ES-SCLC received 1L induction therapy with carboplatin, etoposide and atezolizumab for 4 cycles. Following induction, eligible pts without PD were enrolled and received up to 4 doses of 177 Lu-SSO110 in 6 to 9 week intervals, with up to 3 additional treatments per investigator choice. Activities were escalated from 3.7GBq to 5.2GBq, following a BOIN design with a target DLT rate of 0.30. The primary objective was to investigate the safety and tolerability of 177 Lu-SSO110 with 68 Ga-SSO120 companion imaging in pts on maintenance ICI, with secondary objective of anti-tumor activity of the combination. Concordance between 68 Ga-SSO120 PET/CT and contrast-enhanced CT was an exploratory endpoint. Results: Of the 35 screened pts, 20 were deemed eligible (median age 65.5 years (range 47-83), 55% female, 25% brain mets). With a median 11.1 month follow up (data cut off: 08/12/25), the TEAE rate associated with 177 Lu-SSO110 was 0% at 3.7GBq (dose level 1), 71.4% at 4.5GBq (dose level 2), and 83.3% at 5.2GBq (dose level 3). The grade 3/4 TEAE rate associated with 177 Lu-SSO110 was 0% (dose level 1), 57.1% (dose level 2), and 41.7% (dose level 3). Grade 2 to 4 thrombocytopenia rate related to 177 Lu-SSO110 was 45%. Grade 3/4 irAEs related to ICI was 20%. There was 10% pneumonitis rate attributed to ICI. The treatment interruption rate was 50% and treatment discontinuation rate was 10% (2 attributed to 177 Lu-SSO110 associated thrombocytopenia). From the start of C1 induction chemoICI, the ORR was 85%, including 1 CR. From the start of maintenance ICI, median PFS was 3.7 months and median OS was 8 months. Conclusions: Addition of SSTR2 targeted RPT to maintenance ICI was well tolerated and demonstrated clinically meaningful anti-tumor activity. This supports further investigation of SSTR2-targeted RPT in combination with ICI in patients with ES-SCLC. Clinical trial information: ACTRN12623000185662. ORR, PFS and OS. Efficacy ES-SCLC patients N=20 Best response rates (from C1 induction) CR 1 (5%) PR 16 (80%) SD 3 (15%) ORR (from C1 induction) 17 (85%) Median PFS (months) (from C1 maintenance) 3.7 months Median OS (months) (from C1 maintenance) 8 months

Association of GLP-1 agonists with breast cancer incidence in women.

10506 Background: Excess weight is a key modifiable risk factor for breast cancer. Glucagon-like peptide-1 receptor agonists (GLP-1) promote weight loss and improve markers of metabolic health. However, the effect of GLP-1 on breast cancer risk among women eligible for breast cancer screening remains unclear. Methods: We conducted a retrospective, time-dependent cohort study from January 1, 2022, to June 30, 2025, using electronic health records. We identified 217,025 unique patients who underwent breast imaging, restricting the sample to women aged 45 to 80 years with a BMI greater than 25 and a documented imaging outcome (n=94,827; median age 61). The primary outcome was breast cancer detection. GLP-1 use was defined as a first prescription prior to the exam date and assessed in relation to race, ethnicity, age, and type 2 diabetes. To address potential confounding between these covariates and GLP-1 exposure, we performed one-to-one, case-control matching using propensity scores based on age, race, ethnicity, highest BMI, breast density, and type 2 diabetes diagnosis. Results: Among 94,827 women, 2,314 (2.4%) were diagnosed with breast cancer during the study period, while 92,513 (97.6%) were not. Of the total, 15,107 (15.9%) had GLP-1 exposure, and 79,720 (84.1%) did not. Among those exposed to GLP-1, 249 (1.65%) developed breast cancer, while 14,858 (98.4%) did not. Among women without exposure to GLP-1, there were 2065 (2.6%) women with breast cancer and 77,655 (97.4%) of women without breast cancer. GLP-1 exposure was associated with a lower incidence of breast cancer (OR 0.630 (0.552, 0.720 ); p<0.0001). In the matched logistic regression analysis (30,214 observations; 581 cancer cases), GLP-1 exposure prior to the exam date was associated with a lower incidence of breast cancer (OR 0.746, 95% CI: 0.632–0.880; p<0.0005). Conclusions: In this large observational study of women undergoing breast imaging at a major academic center, GLP-1 treatment was associated with a significantly lower incidence of breast cancer after accounting for age, race, ethnicity, BMI, breast density, and type 2 diabetes status. These findings support the need for prospective trials investigating incretin medications for breast cancer prevention. Matched case-control contingency table for GLP-1 exposure prior to exam date and breast cancer. No cancer Total GLP-1 249 (1.65%) 14858 (98.35%) 15107 No GLP-1 332 (2.20%) 14775 (97.80%) 15107 Total 581 (1.92%) 29633 (98.08%) 30214

High-dose furmonertinib in <i>EGFR</i> -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.

8607 Background: Brain metastases (BM) are common in patients with EGFR -mutated ( EGFR m) non-small cell lung cancer (NSCLC) and are associated with poor prognosis. Furmonertinib is a pan- EGFR tyrosine kinase inhibitor (TKI) characterized by high central nervous system penetration and a wide therapeutic window. This study evaluated the efficacy and safety of high-dose furmonertinib (160 mg once daily) in previously EGFR-TKI-treated patients with EGFR m NSCLC and BM. Methods: iFORCE was a prospective, single-arm study conducted at a single center. Eligible patients had EGFR exon 19 deletion or L858R-mutant NSCLC with at least one measurable intracranial lesion (≥5 mm) and had received ≥1 prior EGFR-TKI therapy. Patients received furmonertinib 160 mg orally once daily. The primary endpoints were intracranial progression-free survival (iPFS). Results: Twenty-three patients were enrolled, with a median follow-up time of 19.7 months (95% confidence interval [CI], 14.5-25.3 months). Median iPFS was 14.6 months (95% CI, 4.2-not reached), with 12- and 24-month iPFS rates of 53.8% and 30.8%, respectively. The intracranial objective response rate (iORR) was 34.8% (95% CI, 16.4-57.3), and the intracranial disease control rate (iDCR) was 91.3% (95% CI, 72.0-98.9). Median systemic progression-free survival (PFS) was 10.7 months (95% CI, 3.9-not reached). Treatment-related adverse events occurred in 13 (56.5%) of patients and were predominantly grade 1; one patient (4.3%) experienced a grade 3 stomatitis. No treatment discontinuations or treatment-related deaths were observed. Conclusions: High-dose furmonertinib demonstrated encouraging intracranial efficacy with a manageable safety profile in previously EGFR-TKI-treated patients with EGFR m NSCLC and BM, supporting further investigation in randomized studies. Clinical trial information: NCT05465343 .

Potential BMI-dependent overall survival differences in postmenopausal breast cancer patients treated with CDK4/6 inhibitors: A Mayo Clinic platform study.

1110 Background: CDK4/6 inhibitors with endocrine therapy are widely used for HR+/HER2– metastatic breast cancer (BC). While studies have shown similar progression-free outcomes across agents, overall survival (OS) data are limited. Since OS is a definitive endpoint and BMI may influence outcomes, this study examines BMI-dependent OS differences among CDK4/6 inhibitors. Methods: A retrospective cohort study was conducted using the Mayo Clinic Platform full AMC1 dataset. Postmenopausal women with BC receiving palbociclib/ribociclib/abemaciclib plus aromatase inhibitor (AI) were included. Patients with prior use of fulvestrant, anthracyclines, radiation therapy, GnRH agonists, or history of MACE, heart failure, myocardial infarction, or stroke before BC diagnosis were excluded. Patients were stratified by BMI and CDK4/6 inhibitor. The primary outcome was 5-year OS. Results: Among 1,989 patients (palbociclib: 868; ribociclib: 465; abemaciclib: 656), palbociclib was associated with significantly worse OS compared to ribociclib in BMI &lt;25 (HR 2.91; 95% CI: 1.76–4.79; P &lt; 0.01) and BMI ≥30 (HR 1.91; 95% CI: 1.21–3.01; P &lt; 0.01). Compared to abemaciclib, palbociclib showed worse OS: BMI &lt;25 (HR 1.73; P &lt; 0.01), BMI 25–30 (HR 1.56; P &lt; 0.01), and BMI ≥30 (HR 1.82; P &lt; 0.01). No significant OS differences were observed between ribociclib and abemaciclib. Palbociclib patients were older, particularly in BMI &lt;25 (Cohen's D = 0.39 vs. ribociclib; 0.27 vs. abemaciclib) and BMI ≥30 (0.28 vs. ribociclib; 0.23 vs. abemaciclib). In the BMI 25–30 group, palbociclib group was also older than ribociclib group (Cohen's D = 0.26). Conclusions: In postmenopausal BC patients on AIs and CDK4/6 inhibitors, palbociclib was associated with worse OS in BMI &lt; 25 and BMI ≥ 30 groups, while ribociclib and abemaciclib showed similar outcomes across BMI groups. Palbociclib patients were older than those on other drugs, which may partially confound results; however, in the BMI 25–30 group, despite similar age differences, no survival difference was observed between palbociclib and ribociclib, suggesting age alone may have limited impact. These findings indicate a potential interaction between BMI and drug choice, and highlight the need for prospective studies to confirm and adjust for these variables. Limitations include the observational design and inability to perform multivariable regression analyses to adjust for confounders. Overall survival comparisons by CDK4/6 inhibitor and BMI subgroup. Comparison BMI Group Hazard Ratio (95% CI) P-value Palbociclib vs Ribociclib &lt;25 2.91 (1.76 – 4.79) &lt; 0.01 25 – 30 1.34 (0.87 – 2.071) 0.17 ≥30 1.91 (1.21 – 3.01) &lt; 0.01 Palbociclib vs Abemaciclib &lt;25 1.73 (1.29 – 2.32) &lt; 0.01 25 – 30 1.56 (1.09 – 2.23) &lt; 0.01 ≥30 1.82 (1.15 – 2.88) &lt; 0.01 Ribociclib vs Abemaciclib &lt;25 1.27 (0.81 – 1.99) 0.29 25 – 30 0.87 (0.54 – 1.43) 0.59 ≥30 1.05 (0.63 – 1.75) 0.85

National inpatient burden of nausea, vomiting, and dehydration during radiotherapy: A HCUP NIS analysis.

e24198 Background: Even when radiotherapy is delivered outpatient, treatment-related nausea, vomiting, and dehydration can precipitate hospitalization, driving cost and morbidity. National estimates of this burden are limited. Methods: We analyzed the HCUP National Inpatient Sample (NIS) for 2016–2022 to identify hospitalizations with radiotherapy encounters (Z51.0) and concurrent diagnoses of nausea, vomiting, or dehydration using ICD-10 codes. Outcomes included length of stay (LOS), total charges, ICU use proxies, in-hospital mortality, and non-home discharge. Survey-weighted national estimates were calculated, and multivariable regression assessed predictors including cancer site proxies, age, comorbidity burden, insurance status, income quartile, and hospital characteristics. Results: Across 7,842 weighted admissions, mean LOS was 4.6 days (SD 2.1), mean total charges $23,400 (SD $8,700), and ICU-level care proxies were required in 12% of admissions. In-hospital mortality was 0.9%, and 21% of patients required non-home discharge. Older age, higher comorbidity burden, lower income quartile, and rural hospital location were independently associated with longer LOS, higher charges, and greater risk of non-home discharge (p &lt; 0.01). Admissions for gastrointestinal or head/neck malignancies had the highest rates of RINV-related hospitalization. Temporal trends showed stable rates over the 7-year period. Conclusions: Hospitalizations for RINV and dehydration during radiotherapy represent a measurable national burden with disparities by socioeconomic status, tumor site, and hospital location. Clinical Takeaway: Targeted outpatient supportive interventions, particularly for high-risk patients, may reduce hospitalization, costs, and morbidity during radiotherapy.